Adamax 1032 Da

Educational overview

Adamax 1032 Da is listed in the ezGLP knowledgebase under Investigational nootropic. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Adamax 1032 Da is the heavier of two structural variants sold by research-chemical vendors under the Adamax name, both of which are derivatives of the Russian nootropic heptapeptide Semax carrying an adamantane cage group and, in most listings, an N-terminal acetyl group. The figure 1032 Da is the approximate molecular weight stated by sellers and is the only feature that reliably distinguishes it from the roughly 984 Da form. Adamantane is a rigid hydrocarbon used in memantine and amantadine to increase lipophilicity and metabolic stability. Adamax has no international nonproprietary name, no independently verified registry entry, and no reference standard, so the identity of any given vial rests on the vendor's certificate.

No peer-reviewed research exists on Adamax in either molecular-weight form. There is no published human trial, animal study, receptor-binding assay, pharmacokinetic measurement, or toxicology report for the adamantane-modified peptide. Sellers instead point to the literature on Semax: a 1997 review by its developers describing effects on memory and attention in Russian studies, a 2006 rat study reporting increased hippocampal BDNF and TrkB expression, and a 2005 study of dopaminergic and serotonergic modulation in rodents. None of that work has been independently replicated outside Russia and Eastern Europe, and none of it examined an adamantane derivative, so the pharmacology of the 1032 Da variant is entirely unknown rather than merely uncertain.

No regulator has approved or reviewed Adamax. Its parent Semax is registered only in Russia and neighbouring countries, and the FDA compounding bulk drug substances review described Semax as presenting immunogenicity risk from aggregation and peptide-related impurities. A chemically modified, untested derivative inherits those concerns and adds the possibility of novel impurities from the additional synthetic steps. In the United States, European Union, United Kingdom, and Australia, Adamax cannot lawfully be marketed for human use and is sold as a research chemical, as a lyophilised powder for reconstitution into nasal spray or injectable form, with labelling that disclaims human consumption. Independent verification of identity, purity, or sterility is not available.

Adamax 1032 Da is shipped as a lyophilised powder that must be reconstituted, and there are no validated stability data for the powder or the solution. Storage guidance can only come from the supplier or a compounding pharmacy label, as the library entry notes. Peptides are sensitive to heat, light, and freeze-thaw cycling, and multi-dose nasal bottles carry contamination risk once opened. Because the two Adamax variants are easily confused and vendors do not always state which they supply, a dose log that records the stated molecular weight, vendor, lot number, diluent, reconstitution date, route, and storage temperature, together with an inventory record of vials on hand, is the only way to keep records unambiguous.

Category

Investigational nootropic

Routes represented

Intranasal / Subcutaneous (SubQ)

Storage context

Investigational; no validated product-specific stability data. Follow the supplier or pharmacy label.